Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 9/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | FRK | P42685 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.39 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12075882 | 0.98 | CYP11B2 (0.50) | CYP11B2CYP11B1TRPV4CASP1EGLN2 | |
| SCHEMBL1819145 | 0.90 | CYP11B2 (0.51) | CYP11B2CYP11B1TRPV4CASP1EGLN2 | |
| SCHEMBL1816188 | 0.74 | NOTUM (0.65) | CYP11B2CYP11B1TRPV4CASP1 | |
| SCHEMBL3080717 | 0.74 | CYP11B2 (0.55) | CYP11B2CYP11B1TRPV4CASP1EGLN2 | |
| Hydrochloric Acid SCHEMBL1814579 | 0.73 | NOTUM (0.63) | CYP11B2CYP11B1TRPV4CASP1 | |
| SCHEMBL22524433 | 0.69 | PGR (0.36) | CYP11B2 | |
| SCHEMBL21084000 | 0.68 | CYP11B2 (0.56) | CYP11B2CYP11B1TRPV4EGLN2ALDH1A1 | |
| SCHEMBL9339628 | 0.68 | VCAM1 (0.42) | CYP11B2CYP11B1TRPV4CASP1EGLN2 | |
| SCHEMBL24186806 | 0.68 | CYP11B2 (0.44) | CYP11B2CYP11B1TRPV4CASP1EGLN2 | |
| SCHEMBL3076212 | 0.68 | IKBKB (0.49) | CYP11B2CYP11B1TRPV4CASP1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| EP-3885340-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2021-09-29 | — | — | EP | disclosed |
| US-11046713-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2021-06-29 | — | — | US | disclosed |
| EP-3369732-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| US-10711013-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2020-07-14 | — | — | US | disclosed |
| US-20190100536-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2019-04-04 | — | — | US | disclosed |
| US-10118933-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2018-11-06 | — | — | US | disclosed |
| EP-3369732-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2018-09-05 | — | — | EP | disclosed |
| US-20170260206-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2017-09-14 | — | — | US | disclosed |
| US-9657003-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2017-05-23 | — | — | US | disclosed |
| EP-3056485-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | Orion Corporation (FI) | 2016-08-17 | — | — | EP | disclosed |
| US-20150203479-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION | 2015-07-23 | — | — | US | disclosed |
| US-8975254-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2015-03-10 | — | — | US | disclosed |
| EP-2493858-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2014-07-02 | — | — | EP | disclosed |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-09-06 | — | — | US | disclosed |
| EP-2493858-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | Orion Corporation (FI) | 2012-09-05 | — | — | EP | disclosed |
| CN-102596910-A | Androgen receptor modulating compounds | ORION CORP | 2012-07-18 | — | — | CN | disclosed |
| WO-2011051540-A9 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011051540-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260206-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | CYP11B2 19/4885CYP11B1 23/4885TRPV4 1537/4885 |
| US-10118933-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | CYP11B2 19/4885CYP11B1 23/4885TRPV4 1537/4885 |
| US-10711013-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | CYP11B2 19/4885CYP11B1 23/4885TRPV4 1537/4885 |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | CYP11B2 19/4885CYP11B1 23/4885TRPV4 1537/4885 |
| US-20190100536-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | CYP11B2 19/4885CYP11B1 23/4885TRPV4 1537/4885 |
| US-11046713-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | CYP11B2 19/4885CYP11B1 23/4885TRPV4 1537/4885 |
| US-20150203479-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | CYP11B2 19/4885CYP11B1 23/4885TRPV4 1537/4885 |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | CYP11B2 19/4885CYP11B1 23/4885TRPV4 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.